 Christina Finlayson
Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 25 | 2017 | 1846 | 1.090 |
Why?
| | Carcinoma, Ductal, Breast | 5 | 2017 | 76 | 0.510 |
Why?
| | Mastectomy, Segmental | 5 | 2017 | 76 | 0.400 |
Why?
| | Receptors, Estrogen | 7 | 2012 | 371 | 0.350 |
Why?
| | Lymph Nodes | 3 | 2007 | 415 | 0.320 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2008 | 99 | 0.310 |
Why?
| | Thoracic Vertebrae | 1 | 2007 | 68 | 0.280 |
Why?
| | Mammography | 1 | 2007 | 101 | 0.280 |
Why?
| | Prostheses and Implants | 1 | 2007 | 135 | 0.270 |
Why?
| | Receptors, Progesterone | 4 | 2012 | 319 | 0.230 |
Why?
| | Receptor, ErbB-2 | 3 | 2012 | 300 | 0.230 |
Why?
| | src Homology Domains | 1 | 2003 | 33 | 0.220 |
Why?
| | Estrogens | 3 | 2012 | 312 | 0.200 |
Why?
| | Vitamin E | 1 | 2000 | 110 | 0.170 |
Why?
| | Phytotherapy | 1 | 2000 | 67 | 0.170 |
Why?
| | Postoperative Hemorrhage | 1 | 2000 | 74 | 0.170 |
Why?
| | Reoperation | 2 | 2017 | 513 | 0.150 |
Why?
| | Tamoxifen | 5 | 2012 | 190 | 0.150 |
Why?
| | Neoplasm Staging | 7 | 2010 | 1162 | 0.150 |
Why?
| | Neoadjuvant Therapy | 3 | 2010 | 305 | 0.140 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 66 | 0.130 |
Why?
| | Pelvic Exenteration | 1 | 1996 | 11 | 0.130 |
Why?
| | Pelvic Neoplasms | 1 | 1996 | 18 | 0.130 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 92 | 0.130 |
Why?
| | Carcinoma, Lobular | 2 | 2017 | 44 | 0.120 |
Why?
| | Hodgkin Disease | 1 | 2016 | 121 | 0.120 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 200 | 0.120 |
Why?
| | Antineoplastic Agents, Hormonal | 4 | 2012 | 138 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2010 | 1145 | 0.110 |
Why?
| | Insulin | 1 | 2003 | 2080 | 0.110 |
Why?
| | Signal Transduction | 3 | 2012 | 4501 | 0.110 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1175 | 0.100 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2012 | 38 | 0.100 |
Why?
| | Radiotherapy, Adjuvant | 3 | 2008 | 182 | 0.100 |
Why?
| | Female | 22 | 2017 | 59324 | 0.090 |
Why?
| | Breast | 2 | 2003 | 138 | 0.090 |
Why?
| | Carcinoma in Situ | 1 | 2011 | 44 | 0.090 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1381 | 0.090 |
Why?
| | Axilla | 2 | 2007 | 39 | 0.090 |
Why?
| | Keratin-5 | 1 | 2010 | 46 | 0.090 |
Why?
| | Radiotherapy | 2 | 2008 | 175 | 0.090 |
Why?
| | Palliative Care | 1 | 1996 | 641 | 0.080 |
Why?
| | Estrogen Receptor alpha | 1 | 2010 | 121 | 0.080 |
Why?
| | BRCA2 Protein | 1 | 2009 | 41 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 61 | 0.080 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2009 | 51 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2010 | 636 | 0.080 |
Why?
| | Humans | 27 | 2017 | 114045 | 0.080 |
Why?
| | Middle Aged | 12 | 2017 | 26605 | 0.080 |
Why?
| | Aromatase Inhibitors | 1 | 2008 | 49 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2008 | 206 | 0.070 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2007 | 117 | 0.070 |
Why?
| | Breast Cyst | 1 | 2006 | 2 | 0.070 |
Why?
| | Carcinoma, Papillary | 1 | 2007 | 74 | 0.070 |
Why?
| | Cyst Fluid | 1 | 2006 | 27 | 0.070 |
Why?
| | Sternum | 1 | 2006 | 17 | 0.070 |
Why?
| | Biomarkers, Tumor | 2 | 2010 | 1032 | 0.070 |
Why?
| | Melatonin | 1 | 2006 | 106 | 0.060 |
Why?
| | Phosphoproteins | 2 | 2008 | 293 | 0.060 |
Why?
| | Liver Neoplasms | 1 | 2009 | 504 | 0.060 |
Why?
| | Carcinoma, Ductal | 1 | 2005 | 11 | 0.060 |
Why?
| | Ki-67 Antigen | 1 | 2005 | 102 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 743 | 0.060 |
Why?
| | Combined Modality Therapy | 4 | 2008 | 1117 | 0.060 |
Why?
| | Retrospective Studies | 5 | 2017 | 12521 | 0.060 |
Why?
| | Bone Neoplasms | 1 | 2006 | 191 | 0.060 |
Why?
| | Retroviridae Proteins, Oncogenic | 1 | 2003 | 10 | 0.060 |
Why?
| | Adult | 11 | 2017 | 30375 | 0.060 |
Why?
| | Oncogene Protein v-akt | 1 | 2003 | 26 | 0.060 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2003 | 56 | 0.060 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 372 | 0.060 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2003 | 72 | 0.050 |
Why?
| | Receptor, Insulin | 1 | 2003 | 93 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2007 | 632 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 228 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 496 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 269 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2007 | 850 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2007 | 2272 | 0.050 |
Why?
| | Mastectomy, Radical | 1 | 2000 | 2 | 0.040 |
Why?
| | Nurse Anesthetists | 1 | 2000 | 3 | 0.040 |
Why?
| | Phosphorylation | 1 | 2003 | 1558 | 0.040 |
Why?
| | Gynecomastia | 1 | 1998 | 4 | 0.040 |
Why?
| | Immunohistochemistry | 3 | 2008 | 1624 | 0.040 |
Why?
| | Cluster Analysis | 2 | 2012 | 452 | 0.040 |
Why?
| | Blood Coagulation | 1 | 2000 | 200 | 0.040 |
Why?
| | Survival Rate | 2 | 2008 | 1638 | 0.040 |
Why?
| | Endocrine System Diseases | 1 | 1998 | 30 | 0.040 |
Why?
| | Aged | 5 | 2017 | 18969 | 0.040 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2012 | 742 | 0.040 |
Why?
| | Preoperative Care | 1 | 2000 | 319 | 0.040 |
Why?
| | Margins of Excision | 1 | 2017 | 29 | 0.040 |
Why?
| | Gene Expression Profiling | 3 | 2008 | 1518 | 0.040 |
Why?
| | Ultrasonography | 1 | 2000 | 635 | 0.030 |
Why?
| | Mastectomy | 2 | 2007 | 99 | 0.030 |
Why?
| | Estradiol | 2 | 2010 | 450 | 0.030 |
Why?
| | Consensus | 1 | 2017 | 532 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 285 | 0.030 |
Why?
| | Lymph Node Excision | 2 | 2009 | 140 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 2000 | 787 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2017 | 489 | 0.030 |
Why?
| | CD24 Antigen | 1 | 2012 | 20 | 0.030 |
Why?
| | Prospective Studies | 1 | 2003 | 6195 | 0.030 |
Why?
| | Breast Neoplasms, Male | 1 | 2012 | 28 | 0.030 |
Why?
| | Patient Selection | 1 | 1996 | 629 | 0.030 |
Why?
| | Hyaluronan Receptors | 1 | 2012 | 90 | 0.020 |
Why?
| | Mass Screening | 1 | 1998 | 979 | 0.020 |
Why?
| | Cell Line, Tumor | 2 | 2010 | 2700 | 0.020 |
Why?
| | Colorado | 2 | 2017 | 4090 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 1996 | 926 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 312 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 258 | 0.020 |
Why?
| | Prognosis | 2 | 2009 | 3315 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2012 | 229 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2011 | 180 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 845 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 552 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 695 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 99 | 0.020 |
Why?
| | Peptide Mapping | 1 | 2010 | 60 | 0.020 |
Why?
| | Databases, Protein | 1 | 2010 | 59 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 134 | 0.020 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 66 | 0.020 |
Why?
| | Observer Variation | 1 | 2010 | 298 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2009 | 214 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 2009 | 125 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 327 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 20 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 170 | 0.020 |
Why?
| | Databases as Topic | 1 | 2008 | 63 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2010 | 438 | 0.020 |
Why?
| | Perilipin-1 | 1 | 2008 | 16 | 0.020 |
Why?
| | Estrogen Receptor Modulators | 1 | 2008 | 17 | 0.020 |
Why?
| | Interferon-beta | 1 | 2008 | 79 | 0.020 |
Why?
| | Doxorubicin | 1 | 2009 | 286 | 0.020 |
Why?
| | S100 Proteins | 1 | 2008 | 37 | 0.020 |
Why?
| | Perimenopause | 1 | 2008 | 61 | 0.020 |
Why?
| | Androstadienes | 1 | 2008 | 97 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2008 | 275 | 0.020 |
Why?
| | SEER Program | 1 | 2008 | 195 | 0.020 |
Why?
| | Mastectomy, Modified Radical | 1 | 2007 | 6 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2008 | 308 | 0.020 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2007 | 26 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1143 | 0.020 |
Why?
| | Transcriptome | 1 | 2012 | 723 | 0.020 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2007 | 49 | 0.020 |
Why?
| | Dehydroepiandrosterone Sulfate | 1 | 2006 | 45 | 0.020 |
Why?
| | Mice, Nude | 1 | 2008 | 628 | 0.020 |
Why?
| | Epidermal Growth Factor | 1 | 2006 | 160 | 0.020 |
Why?
| | Quality of Life | 1 | 1996 | 2343 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 260 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2007 | 385 | 0.010 |
Why?
| | Mice | 2 | 2012 | 14843 | 0.010 |
Why?
| | Proteomics | 1 | 2010 | 815 | 0.010 |
Why?
| | Patient Care Planning | 1 | 2005 | 138 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2006 | 445 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 694 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 9049 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2005 | 332 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 847 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2173 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1331 | 0.010 |
Why?
| | Postmenopause | 1 | 2005 | 301 | 0.010 |
Why?
| | Phenotype | 1 | 2010 | 2784 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 2764 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1356 | 0.010 |
Why?
| | Liver | 1 | 2009 | 1633 | 0.010 |
Why?
| | United States | 1 | 2017 | 12137 | 0.010 |
Why?
| | Apoptosis | 1 | 2010 | 2349 | 0.010 |
Why?
| | Biopsy | 1 | 2005 | 1024 | 0.010 |
Why?
| | Age Factors | 1 | 2008 | 2885 | 0.010 |
Why?
| | Hospitals, Private | 1 | 1999 | 11 | 0.010 |
Why?
| | Hospitals, County | 1 | 1999 | 10 | 0.010 |
Why?
| | Hospitals, University | 1 | 1999 | 169 | 0.010 |
Why?
| | Animals | 2 | 2012 | 31565 | 0.010 |
Why?
| | Leydig Cell Tumor | 1 | 1998 | 8 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2010 | 6306 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2009 | 5038 | 0.010 |
Why?
| | Male | 3 | 2012 | 55396 | 0.010 |
Why?
| | Pregnancy | 1 | 2009 | 5499 | 0.010 |
Why?
| | Testicular Neoplasms | 1 | 1998 | 96 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2008 | 1875 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 1998 | 544 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 1999 | 1080 | 0.010 |
Why?
| | Risk Factors | 1 | 2008 | 8614 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 1999 | 666 | 0.010 |
Why?
| | Adolescent | 1 | 1998 | 17800 | 0.000 |
Why?
|
|
Finlayson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|